BioSpace News Archive

BIOTRONIK’s state-of-the-art LiveSupport feature was used to remotely support two BIOMONITOR Implantable Cardiac Monitor (ICM) implants shortly after launch.

A recent report provides crucial insights along with application based and forecast information in the Global Anti Peptic Ulcer Drugs Market.

The global Bone Morphogenetic Protein (BMP) 2 market size is projected to reach US$ 675.7 million by 2030, from US$ 498.1 million in 2021, at a CAGR of 4.4% during 2022-2030.

The global Darbepoetin Alfa market size is estimated to be worth US$ 4904 million in 2021 and is forecast to a readjusted size of US$ 4010.1 million by 2028 with a CAGR of -2.8% during the forecast period 2022-2030.

The global Diabetes Drugs market size is estimated to be worth US$ 53520 million in 2021 and is forecast to a readjusted size of US$ 78200 million by 2030 with a CAGR of 5.5% during the forecast period 2022-2030.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), today announced the first patient has been dosed in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

The global Hypromellose Acetate Succinate market size is estimated to be worth US$ 42 million in 2021 and is forecast to a readjusted size of US$ 60 million by 2030 with a CAGR of 5.2% during the forecast period 2022-2030.

The global Infertility Drugs market size is projected to reach US$ 7494.8 million by 2030, from US$ 5164 million in 2021, at a CAGR of 5.4% during 2022-2030.

Mylab Discovery Solutions, India’s leading biotechnology company, and Portland, OR-based Hemex Health, a medical diagnostic device company focused on creating diagnostics to transform frontline healthcare, announced the official launch of the Gazelle™ PathoCatch™ COVID-19 FIA test, their collaborative diagnostic solution for point-of-care (POC) testing in India.

Inspire Medical Systems, Inc. today announced that the United States Food and Drug Administration (FDA) has approved additional magnetic resonance imaging (MRI) scan conditions for use with Inspire therapy.